Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interactions Between Delta-9-THC and CBD
NCT06859710Phase 1Recruiting
- Sponsor
- University of California, Los Angeles
- Start
- Nov 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of cannabidiol in pain and cannabis use disorder (CUD) (8 arms), sponsored by University of California, Los Angeles. Primary endpoints: Subject-rated drug effects of abuse liability at 3 hours, Analgesia as measured using the Cold Pressor Test at 3 hours and 2 more. Started Nov 2025; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
paincannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT06859710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06859710.